Study S000344

Glucagon-like Peptide-1's Effect on Renal Regional Blood Flow and the Renal Function in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06555146
Acronym: Sema-RMA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 15
Start: 2024-08
Primary completion: 2025-03
Lead sponsor: Bispebjerg Hospital
Conditions: Diabetes Mellitus, Type 2; Kidney Disease, Chronic
Interventions: DRUG:Semaglutide, 0.5 mg/mL; DRUG:Placebo, Saline
Results posted: FALSE

Registered primary outcomes

Total blood flow [Measured during 30 minutes of MRI. One measurement will be done on each study day, a total of 4 measurements for each participant, over the span of the study (approximately 1 year).]
Regional renal perfusion [Measured during 30 minutes of MRI. One measurement will be done on each study day, a total of 4 measurements for each participant, over the span of the study (approximately 1 year)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT06555146; registry reference DERIVED:39963952